Yesterday the 11th SwedenBIO Award was announced and the lucky winner was Oncopeptides.
Oncopeptides received the award for its work in developing treatment against hematologic cancer. After several year of professional development work, Oncopeptides was able to present positive clinical phase II results with their drug candidate Ygalo in patients with Multiple Myeloma. Based on these clinical results the company finalized its work in defining a complete enrollment program, which was approved by both the European and the US Medicine Agencies. The company went IPO in February 2017, one of the largest capital procurements in the Swedish biotech history, according to SwedenBIO’s press release. The capital base and broad ownership that Oncopeptides has secured increases the possibility that the company could remain in Sweden.
The Award consist of, besides the great honor, of a challenge prize and two delegate tickets to the Nordic Life Science Days September 12-14 2017.
Photo of Jakob Lindberg, CEO Oncopeptides.